Posted On: 09/02/2014 1:48:25 PM
Post# of 30066
I personally don't believe penetrating the BBB for MANF in PD will be a problem. I believe that is how they currently are delivering GDNF in clinical trials for PD in the UK. And from a very small lab test using rodents, they have shown MANF to be superior to GDNF in some regards. CED should be a shoe-in for MANF delivery to the inner brain.
And as for the toxicology concerns, MANF is a organic molecule that naturally forms in the human body, I feel confident this will be a nonissue.
CED is the only type of delivery currently possible for PD, AD, CTE. I am not sure how they will deliver it for the other indications.
I found this very interesting. This is a link to a solicitation for enrollment in the UK clinical trials. If you would like to see a diagram of the CED apparatus scroll down to pg. 11. If you look closely at diagram "C" you can see the catheters going to the inner brain. This is the bi-lateral delivery that has been mentioned before.
http://www.parkinsons.org.uk/sites/default/fi...osheet.pdf
Fascinating stuff,
GO AMBS
And as for the toxicology concerns, MANF is a organic molecule that naturally forms in the human body, I feel confident this will be a nonissue.
CED is the only type of delivery currently possible for PD, AD, CTE. I am not sure how they will deliver it for the other indications.
I found this very interesting. This is a link to a solicitation for enrollment in the UK clinical trials. If you would like to see a diagram of the CED apparatus scroll down to pg. 11. If you look closely at diagram "C" you can see the catheters going to the inner brain. This is the bi-lateral delivery that has been mentioned before.
http://www.parkinsons.org.uk/sites/default/fi...osheet.pdf
Fascinating stuff,
GO AMBS
(0)
(0)
